HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $16
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $16.
HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $16.